Modelling a minimal residual disease-based treatment strategy in childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 122, Issue 1, 2003, Pages 30-38

  Campbell, Peter J ^a,b   Morley, Alexander A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Computer modelling; Leukaemia; Minimal residual disease; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; COMPUTER MODEL; DIAGNOSTIC ACCURACY; EVENT FREE SURVIVAL RATE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MINIMAL RESIDUAL DISEASE; MORTALITY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PUBLICATION; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MODELS, THEORETICAL; NEOPLASM, RESIDUAL; PATIENT SELECTION; RECURRENCE; SURVIVAL ANALYSIS;

EID: 0038007436     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04356.x     Document Type: Article

References (22)

1. Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., Pui, C.H. & Masera, G. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine, 342, 998-1006.
2. Biondi, A., Valsecchi, M.G., Seriu, T., D'Aniello, E., Willemse, M.J., Fasching, K., Pannunzio, A., Gadner, H., Schrappe, M., Kamps, W.A., Bartram, C.R., van Dongen, J.J. & Panzer-Grumayer, E.R. (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia, 14, 1939-1943.
3. Brisco, M.J., Condon, J., Hughes, E., Neoh, S.H., Sykes, P.J., Seshadri, R., Toogood, I., Waters, K., Tauro, G., Ekert, H. & Morley, A.A. (1994) Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet, 343, 196-200.
4. Brisco, M.J., Hughes, E., Neoh, S.H., Sykes, P.J., Bradstock, K., Enno, A., Szer, J., McCaul, K. & Morley, A.A. (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood, 87, 5251-5256.
5. Brisco, M.J., Sykes, P.J., Hughes, E., Dolman, G., Neoh, S.H., Peng, L., Toogood, I. & Morley, A.A. (1997) Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 99, 314-319.
6. Brisco, M.J., Sykes, P.J., Hughes, E., Neoh, S.-H., Snell, L.E., Dolman, G., Peng, L.-M., Toogood, I.R.G., Cheney, K., Rice, M.S., Story, C.J. & Morley, A.A. (2001) Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia, 15, 385-390.
7. Cave, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia. New England Journal of Medicine, 339, 591-598.
8. Chessells, J.M., Bailey, C., Wheeler, K. & Richards, S.M. (1992) Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X, Lancet, 340, 565-568.
9. Childhood ALL Collaborative Group (1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children, Lancet, 347, 1783-1788.
10. Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.E., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691-2696.
11. Deming, W.E. (1950) Some Theory of Sampling. John Wiley & Sons Inc, New York, NY.
12. van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731-1738.
13. Donovan, J.W., Ladetto, M., Zou, G., Neuberg, D., Poor, C., Bowers, D. & Gribben, J.G. (2000) Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood, 95, 2651-2658.
14. Dresch, C., Faille, A., Poirier, O. & Kadouche, J. (1974) The cellular composition of the granulocyte series in the normal human bone marrow according to the Volume of the sample. Journal of Clinical Pathology, 27, 106-108.
15. Goulden, N.J., Knechtli, C.J., Garland, R.J., Langlands, K., Hancock, J.P., Potter, M.N., Steward, C.G. & Oakhill, A. (1998) Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. British Journal of Haematology, 100, 235-244.
16. Gruhn, B., Hongeng, S., Yi, H., Hancock, M.L., Rubnitz, J.E., Neale, G.A. & Kitchingman, G.R. (1998) Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia, 12, 675-681.
17. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Laukester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998) Minimal residual disease before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukaemia. Blood, 92, 4072-4079.
18. Nachman, J., Sather, H.N., Gaynon, P.S., Lukens, J.N., Wolff, L. & Trigg, M.E. (1997) Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukaemia and unfavourable presenting features: a report from the Children's Cancer Group. Journal of Clinical Oncology, 15, 2222-2230.
19. Pui, C.-H. (1995) Childhood leukemias. New England Journal of Medicine, 332, 1618-1630.
20. Roberts, W.M., Estrov, Z., Ouspenskaia, M.V., Johnston, D.A., McClain, K.L. & Zipf, T.F. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 336, 317-323.
21. Sykes, P.J., Brisco, M.J., Hughes, E., Snell, L.E., Dolman, G., Neoh, S.-H., Peng, L.-M., Toogood, I., Venables, W.N. & Morley, A.A. (1998) Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: is the disease multifocal? British Journal of Haematology, 103, 60-65.
22. Wheeler, K.A., Richards, S.M., Bailey, C.C., Gibson, B., Hann, I.M., Hill, F.G. & Chessells, J.M. (2000) Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI, Blood, 96, 2412-2418.